GE HealthCare secures dual US and European regulatory approvals for its new Allia Moveo imaging system, designed to enhance patient comfort and streamline clinical workflows in minimally invasive procedures.
Despite a recent $1.5 billion capital raise sparking acquisition speculation, SoFi's leadership indicates a disciplined approach to deals, prioritizing organic growth and strategic product expansion over costly buyouts.
The prominent value investment firm has initiated a significant new position in UniFirst, a uniform and facility services provider, signaling confidence in its recurring revenue model despite recent stock underperformance.
Amazon Web Services warns that multi-year delays in securing power grid connections are jeopardizing its data center investments across Europe, highlighting a critical infrastructure bottleneck for the continent's digital and industrial ambitions.
CNBC's Jim Cramer highlights Reddit (NYSE: RDDT) in his latest market strategy, pointing to its extreme price swings and speculating on a near-term rise. The social media platform's stock continues to draw attention for its reactive trading patterns.
CNBC's Jim Cramer expresses strong confidence in Affirm Holdings ahead of its earnings, crediting CEO Max Levchin's leadership for potentially outperforming market expectations and challenging bearish sentiment.
After years of losses, Evolent Health has broken into profitability with a rising capital base. While its Return on Capital Employed (ROCE) remains low, the accelerating trend suggests a potential inflection point for the healthcare services firm.
Pfizer's shares have staged a notable rebound in recent months, drawing investor attention as the company pivots towards oncology. We examine whether the current valuation reflects its long-term growth potential or lingering post-pandemic challenges.
Aquestive Therapeutics faces a regulatory delay for its sublingual epinephrine film, Anaphylm, after the FDA raised concerns primarily about its packaging and labeling. The company views the issues as solvable and is moving forward with redesigns and new studies, aiming for a 2026 resubmission while advancing parallel filings abroad.
Nike is consolidating its outdoor ambitions, merging its ACG and trail running lines into a dedicated performance brand. The strategic pivot targets a lucrative market as the sportswear giant seeks to reinvigorate growth against a backdrop of a multi-year stock decline.
UnitedHealth Group shares have tumbled nearly 47% over the past year, significantly underperforming the broader market and raising urgent questions about its valuation. While a standard discounted cash flow model suggests the stock is deeply undervalued, investors are weighing the model's optimistic assumptions against mounting regulatory and operational headwinds in the healthcare sector.
A series of class action lawsuits alleging misleading statements about the progress of Ramaco Resources' Brook Mine project has cast a shadow over the company's disclosure practices and market valuation, shifting investor focus from operational metrics to governance credibility.
As freezing temperatures grip the nation, federal regulators and consumer advocates are sounding the alarm on a predictable wave of scams. Fraudsters are exploiting the weather, posing as utility companies to pressure victims into immediate payments.
A wave of panic selling has engulfed the software sector, with even giants like Microsoft not spared. Investors are fleeing on fears that artificial intelligence will erode pricing power, competitive advantages, and long-term growth, creating what traders are calling a 'SaaSpocalypse'.
Stani Kulechov, founder of the decentralized finance protocol Aave, has purchased a luxury five-story residence in London's Notting Hill for £22 million, reportedly below asking price, as crypto entrepreneurs increasingly invest in traditional real estate assets.
CNBC's Jim Cramer has spotlighted healthcare distributor McKesson Corp., noting its history of post-earnings rallies. However, the 'Mad Money' host cautions that aggressive regulatory rhetoric from the White House could unsettle the entire sector.
CNBC's Jim Cramer suggests Chipotle Mexican Grill's stock, despite potential for a muted quarter, may be poised for a rebound given its depressed valuation, highlighting it in his weekly market game plan.
CNBC's Jim Cramer expresses apprehension ahead of Advanced Micro Devices' quarterly report, suggesting even strong results may not satisfy a market exhibiting a new, unforgiving pattern toward chip stocks.
CNBC's Jim Cramer has spotlighted Merck & Co. as a strategic holding, praising the pharmaceutical giant's acquisition-driven strategy to build a more balanced portfolio ahead of its blockbuster drug's patent cliff.
As the artificial intelligence boom enters a new phase of enterprise deployment, investors are looking beyond pure software to the foundational hardware layer. We analyze three key companies powering the AI revolution and why their roles may offer a compelling, lower-risk investment thesis this February.
